A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate and compare the effect of iron isomaltoside
1000 to placebo in its ability to increase haemoglobin (Hb) in subjects with IDA when oral
iron preparations are ineffective or cannot be used.